(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.
Struggling Novavax struck a $1.4 billion deal with Sanofi on Friday to commercialize its existing COVID-19 vaccine and develop a combined jab to protect against both the coronavirus and influenza ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to Pfizer and Moderna, signed a licensing agreement with Sanofi to ...
Don’t call it a comeback: Novavax just (briefly) became a meme stock. The Maryland-based biotech joined the likes of Ango American, Vodafone and the notorious GameStop in a resurgence of the meme ...
Gaithersburg’s Novavax says it will have an updated Covid-19 vaccine ready after an FDA committee voted unanimously on the ...
Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi ...
This news sent a shockwave through the market, rewarding both long-term holders and savvy traders who capitalised on the short-term hype. But is this a sign of a long-term turnaround for Novavax ...